Human Clinical Efficacy Data for ChromaDex®'s Patented pTeroPure® (pterostilbene) to be Presented at American Heart Association's High Blood Pressure Research 2012 Scientific Sessions - Results Show Effects of pTeroPure on Blood Pressure and Other Metabolic Parameters in Adults -
IRVINE, Calif., Aug. 9, 2012 /PRNewswire/ -- ChromaDex® Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries announced today that the human clinical data for its patented pTeroPure® (pterostilbene) study was accepted for presentation at the High Blood Pressure Research 2012 Scientific Sessions, sponsored by the American Heart Association's Council for High Blood Pressure Research and Council on Kidney in Cardiovascular Disease. The presentation will be September 20, 2012, in Washington, D.C.
The study — an eight week, double-blind, randomized, placebo-controlled trial — included 80 adults who were given either a placebo or 100 milligrams or 250 milligrams of pTeroPure per day to evaluate pTeroPure's effects on blood pressure, weight loss and cholesterol. Led by principle investigator Dr. Daniel Riche, PharmD, Cardiometabolic Clinic Coordinator at the University of Mississippi School of Pharmacy, the study was a collaboration between the University of Mississippi and ChromaDex.
"We are proud to be able to present the efficacy results for pterostilbene at the American Heart Association Scientific Sessions. Pterostilbene is a promising ingredient in the area of cardiometabolics," said Dr. Riche. "The study's endpoints of blood pressure, weight and cholesterol are important health parameters for most Americans and ones that I manage for my patients on a daily basis."
The safety data from the clinical trial was previously presented at the 6th World Congress on Polyphenols Applications in Paris, France, on June 7, 2012. The results showed a lack of adverse reactions with no major adverse events supporting the safety of pterostilbene.
"Presentation of the pTeroPure human clinical data is a significant milestone for ChromaDex. Being accepted by the American Heart Association to present at this nationally renowned meeting, which focuses on blood pressure, is an outstanding platform to showcase the benefits of this amazing ingredient," said Frank Jaksch, Jr., CEO and co-founder of ChromaDex. "We believe this milestone will allow ChromaDex to advance numerous business development opportunities to monetize its exclusive worldwide patent rights for pTeroPure in both the vast over-the-counter and pharmaceutical markets."
Pterostilbene is an antioxidant found in blueberries and other berries and is believed by many experts to have a number of health benefits. Pterostilbene has superior biological activity, , , , , better oral bioavailability, ,  and metabolizes more slowly in the body than other antioxidant polyphenols (substances from plants that tend to prevent or neutralize the damaging effects of free radicals), resulting in more prolonged antioxidant activity, , , . Along with a number of other effects, pterostilbene has shown great promise for supporting heart health, , , ,  , cognitive function,  and anti-aging, .
pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan.
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products include patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
Alex Partners, LLC
Scott Wilfong, President
Laura Carney, Executive Assistant
*Statements in the release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
 Rimando AM, Nagmani R, Feller DR, and Yokoyama W. Pterostilbene, a new agonist for the peroxisome proliferator activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J. Agric. Food Chem. 53, 3403 (2005).
 Perecko T, Jancinova V, Drabikova K, Nosal R, Harmatha J. Structure efficiency relationship in derivatives of stilbene. Comparison of resveratrol, pinosylvin and pterostilbene. Neuro. Endocrinol. Lett. 29(5), 802 (2008).
 Joseph JA, Fisher DR, Cheng V, Rimando AM, and Shukitt-Hale B. Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J. Agric. Food Chem. 56, 10544 (2008).
 Billack B, Radkar V, Adiabouah C. In vitro evaluation of the cytotoxic and antiproliferative properties of resveratrol and several of its analogs. Cell. Mol. Biol. Lett. 13, 553 (2008).
 Meng XL, Yang JY, Chen GL, Wang LH, Zhang LJ, Wang S, Li J, Wu CF. Effects of resveratrol and its derivatives on lipopolysaccharide induced microglial activation and their structure activity relationships. Chem. Biol. Interact. 174(1), 51 (2008).
 Asensi M, Medina I, Ortega A, Carretero J, Carmen Bano M, Obrador E, Estrela JM. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 33, 387 (2002).
 Roupe KA, Remsberg CM, Yáñez JA, Davies NM. Pharmacometrics of stilbenes: seguing towards the clinic. Curr. Clin. Pharmacol. 1, 81 (2006).
 Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. (2010 Nov 30. Epub ahead of print).
 Remsberg CM, Yáñez JA, Ohgami Y, VegaVilla KR, Rimando AM, Davies NM. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother. Res. 22, 169 (2008).
 Ferrer P, Asensi M, Segarra R, Ortega A, Benlloch M, Obrador E, Varea MT, Asensio G, Jordá L, Estrela JM. Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia 7, 37 (2005).
 Pan Z, Agarwal AK, Xu T, Feng Q, Baerson SR, Duke SO, Rimando AM. Identification of molecular pathways affected by pterostilbene, a natural dimethylether analog of resveratrol. BMC Med. Genomics. 1, 7 (2008).
 Pons L. Agricultural Research/November-December 2006. This work is part of Plant Biological and Molecular Processes(#302) and Quality and Utilization of Agricultural Products (#306), two ARS National Programs described on the World Wide Web at www.nps.ars.usda.gov.
 Mizuno CS, Ma G, Khan S, Patny A, Avery MA, Rimando AM. Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARalpha. Bioorg. Med. Chem. 16(7), 3800 (2008).
 Park ES, Lim Y, Hong JT, Yoo HS, Lee CK, Pyo MY, Yun YP. Pterostilbene, a natural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway. Vascul Pharmacol. 53, 61 (2010).
 Shukitt-Hale B, Lau FC, Joseph JA. Berry Fruit Supplementation and the Aging Brain. J. Agric. Food Chem. 56, 636 (2008).
SOURCE ChromaDex Corporation